Citadel Advisors
LYEL icon

Citadel Advisors’s Lyell Immunopharma LYEL Stock Holding History

Citadel Advisors’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$251K Buy
+17,900
New +$324K ﹤0.01% 11528
2026
Q1 		– Sell
-16,000
Closed -$492K – 13698
2025
Q4 		$492K Sell
16,000
-750
-4% -$16.8K ﹤0.01% 9059
2025
Q3 		$272K Buy
16,750
+760
+5% +$8.68K ﹤0.01% 10588
2025
Q2 		$141K Buy
15,990
+15,690
+5,230% +$143K ﹤0.01% 11008
2025
Q1 		$3.23K Sell
300
-465
-61% -$5.7K ﹤0.01% 13980
2024
Q4 		$9.79K Buy
765
+755
+7,550% +$15K ﹤0.01% 13627
2024
Q3 		$276 Sell
10
-365
-97% -$10.7K ﹤0.01% 14059
2024
Q2 		$10.9K Buy
375
+80
+27% +$3.81K ﹤0.01% 13064
2024
Q1 		$13.2K Buy
295
+225
+321% +$9.63K ﹤0.01% 13312
2023
Q4 		$2.72K Sell
70
-40
-36% -$1.44K ﹤0.01% 13666
2023
Q3 		$3.23K Sell
110
-60
-35% -$2.85K ﹤0.01% 13613
2023
Q2 		$10.8K Buy
170
+10
+6% +$553 ﹤0.01% 13175
2023
Q1 		$7.55K Buy
160
+60
+60% +$3.21K ﹤0.01% 13711
2022
Q4 		$6.94K Buy
+100
New +$9.93K ﹤0.01% 13869
2022
Q2 		– Sell
-610
Closed -$62K – 13602
2022
Q1 		$62K Sell
610
-150
-20% -$18.2K ﹤0.01% 12655
2021
Q4 		$118K Buy
+760
New +$169K ﹤0.01% 12544

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Citadel Advisors's LYEL Position: Q2 2026 in Review

Citadel Advisors reduced its Lyell Immunopharma (LYEL) stake by 95% in Q2 2026, selling an estimated $6.57M and leaving 18,695 shares worth $263K. The position accounts for ﹤0.01% of the portfolio, ranked #11425.

Citadel Advisors first reported a position in LYEL in Q2 2021 and has held it in 19 quarters since. The position peaked at $9.99M in Q4 2025. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Citadel Advisors held 18,695 shares of Lyell Immunopharma worth $263K as of Q2 2026.
  • Citadel Advisors sold 362,767 Lyell Immunopharma shares in Q2 2026, an estimated $6.57M.
  • Lyell Immunopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11425 holding.
  • Citadel Advisors first reported a position in Lyell Immunopharma in Q2 2021 and has held it in 19 quarters since.
  • Citadel Advisors's Lyell Immunopharma position peaked at $9.99M in Q4 2025.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.